Recently, Hangzhou RoboCT Technology Development Co., Ltd. (hereinafter referred to as "RoboCT") announced the completion of nearly 100 million RMB in Series B financing. This round of financing was led by Xi Venture Capital, and Haoyue Capital served as the exclusive financial advisor. The funds will be mainly used for the development and iteration of embodied intelligent exoskeleton technology, the development of new brain-computer products, the expansion of production bases, and global market expansion, further promoting the application of embodied intelligent exoskeleton wearable robotics in rehabilitation and elderly-care, accelerating the expansion of domestic and overseas networks, and building a world-leading exoskeleton technology company.

Self-developed Technology Builds Barriers and Solves the Core Pain Points of Healthcare Industry

Facing the dual challenges of "imbalance between supply and demand" and "technical barriers" in China's rehabilitation market, RoboCT Technology has launched innovative solutions through the deep integration of embodied intelligent exoskeleton robotics and AI. 

The independently developed rehab exoskeleton products and solutions integrate multimodal biological signal fusion algorithms including electromyography, electroencephalography, spinal electrometry, and motion posture to generate dynamic rehabilitation paths for users, pushing exoskeleton technology to a higher level of precision, with an intention recognition accuracy of 98.7%, which not only increases the average daily service efficiency by 3 times, but also promotes an increase in the gait training efficiency of stroke users by about 53%.

At present, RoboCT has formed a medical-grade product matrix covering all scenarios such as neurological rehabilitation, musculoskeletal rehabilitation, and action compensation, serving more than 623,000 users in total, and the total walking mileage of users can circle the earth twice. The new generation of rehab exoskeleton products equipped with brain-computer interface, spinal electrical stimulation, and "brain-spinal fusion" series have cooperated with top institutions such as Xuanwu Hospital and Huashan Hospital, and successfully implemented multiple cases of "spinal cord electrical stimulation + exoskeleton" collaborative treatment, witnessing a user case where he could not walk after a year after being injured in a car accident, and was able to stand independently 14 days after the operation, and completed 5 meters of independent walking in 28 days. 

The experiment is being expanded across the country, and there are successful cases in more than 14 cities from Hainan to Xinjiang and Heilongjiang provinces. This also marks that RoboCT has taken another step towards human-machine integration and using exoskeleton robotics to promote human evolution.

From Medical Care to Universal Enhancement, Redefining the Boundaries of Human-computer Interaction

The founding team and R&D team of RoboCT have been deeply involved in the field of exoskeleton for more than ten years. With "self-developed technology + cost reconstruction" as the core competitiveness, they have successfully achieved 100% localization of core components, with module costs only 1/10 of the industry, and the gross profit of the whole machine is more than 2 times the industry average. 

It is also an important supplier of core components of embodied intelligent technology hardware, and has served various robotics companies in 40 countries and regions at home and abroad. More importantly, RoboCT is breaking the inherent label of exoskeleton "medical equipment", accelerating its penetration into the consumer market and global scenarios, and re-consolidating its core position in hardware solutions in the field of embodied intelligent technology.

RoboCT's new series of exoskeleton products extend the application of exoskeletons from medical scenarios to home communities and outdoor leisure. The EasyGo assistive exoskeleton, which will be launched in 2025, targets consumer scenarios such as elderly walking assistance and outdoor sports. 

The product uses lightweight carbon fiber materials and bionic structures, can provide walking assistance without power supply, and is priced at only around ￥2500. When thousand-yuan exoskeletons enter the home, it will effectively promote the evolution of embodied exoskeleton from "medical devices" to "extension of human functions", redefine the concept of human-computer interaction, and further unleash broader business imagination.

Policy Support + Capital Support, Contributes to the Global Trillion-dollar Silver Economy 

In 2023, the "14th Five-Year Plan" for the Development of the Robot Industry clearly lists rehabilitation robots as a key direction; 11 provinces and cities including Beijing, Jiangsu, and Hebei have included exoskeleton treatment in medical insurance, reducing patient payment costs by more than 60%. 

At the same time, the superposition of the "silver economy" and the "robot +" policy has pushed the industry into a period of explosive growth. It is estimated that the scale of China's rehabilitation robot market will exceed 20 billion yuan in 2025, with an annual compound growth rate of 47.3%.

The Chinese government's support for healthcare industry has accelerated the development of exoskeleton technology. With the dual support of policies and capital, RoboCT is also constantly expanding its global layout. The classic UGO series of rehabilitation exoskeleton products will obtain the EU CE certification at the end of 2024, helping to accelerate the development of Southeast Asia, the Middle East, Australia and Europe. 

The globalization process of rehab exoskeleton has entered a new stage. At the same time, RoboCT's GoGo assitive exoskeleton, which are expected to be launched in the second half of 2025, will be open to consumers through overseas crowdfunding, further promoting the effective coverage of embodied smart products. The implementation of the new factory after this financing will effectively guarantee the production and global supply of exoskeleton robot equipment.

Reshaping the Value of Life with the Warmth of Science and Technology

Against the backdrop of the global aging population and the explosion of health care needs, embodied intelligent wearable exoskeleton is accelerating from "science fiction imagination" to "universal reality". In this process, the original intention of the founding team and the power of capital resonate: technological breakthroughs require the persistence of long-termists, and industrial transformation is inseparable from the foresight of strategic investors.

Dr. WANG Tian, founder of RoboCT Technology, believes that "technology should serve everyone, especially those who cannot live independently due to physical reasons. Robotics technology is meant to make people live more easily, decently and with dignity. This concept also prompts us to continue to explore and innovate in the field of exoskeleton. Exoskeleton robotics are not just a product for rehabilitation and elderlycare, but an independent robot category. You will also see more applications in entertainment, industry, security, transportation and other fields.

The choice of well-known investors such as Xi Venture Capital confirms the capital market's firm confidence in the "hard technology + big health" track. In the blue ocean of the trillion-dollar silver economy, RoboCT is using technology to benefit the public, using technology to reshape the value of life.

Xi Venture Capital said: "RoboCT is one of the few companies that has both technical depth and commercialization capabilities. Its localized mass production capabilities, globalization strategy and accurate grasp of policies have allowed us to see the leapfrog potential of exoskeleton from "solving pain points" to "creating value." We are optimistic about its dual potential in the rehabilitation and elderly-care and consumer markets, and look forward to it leading Chinese technology to the world."